Shareholder Letters
NEW: AsIDNA™ Letters!
The clinical development of AsiDNA™ is well on its way and we would like to inform you regularly about the progress being made through a Letter dedicated to this first-in-class candidate.
PREVIOUS SHAREHOLDER LETTERS